Replies to post #255774 on Biotech Values

[DewDiligence]

LENZ -23% on what I presume was investor discontent with the Vizz launch:

https://www.globenewswire.com/news-release/2025/11/05/3181420/0/en/LENZ-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Corporate-Highlights.html

As noted in the post I'm replying to, I'm bearish on the commercial prospects.